Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

INTRODUCTION: As most patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. Afatinib has been shown to be more effective in in vitro st...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Nobuaki, Hashimoto, Hisashi, Kamimaki, Chisato, Nagasawa, Ryo, Tanaka, Katsushi, Kubo, Sousuke, Katakura, Seigo, Chen, Hao, Hirama, Nobuyuki, Ushio, Ryota, Aoki, Ayako, Nakashima, Kentaro, Teranishi, Shuhei, Manabe, Saki, Watanabe, Hiroki, Horita, Nobuyuki, Watanabe, Keisuke, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396380/
https://www.ncbi.nlm.nih.gov/pubmed/32495514
http://dx.doi.org/10.1111/1759-7714.13503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396380/
https://www.ncbi.nlm.nih.gov/pubmed/32495514
http://dx.doi.org/10.1111/1759-7714.13503

Ejemplares similares